Amgen, a lead global biotechnology company, revealed plans to expand their commercial operations by investing in additional manufacturing and R & D; operation in the United States and Europe. Amgen intends to invest $1 billion in new process development and bulk manufacturing in Cork, Ireland. It expects to break ground in Cork in 2009 and employ more than 1,100 people in the Irish facility by 2010. It also plans to add a manufacturing plant in Puerto Rico to produce drugs EPOGEN and Aranesp. The announcement also included plans to expand existing research and development operations in Cambridge, Mass., San Francisco, Seattle and Cambridge, U.K as well as build a new development center in Uxbridge, U.K Amgen is moving its European headquarters from Lucern to Zug, Switzerland, and formed a new branch, also in Zug, called Amgen International in order to be more accessible to the market in Central and Southeast Asia, Africa and Latin America.
Amgen Investing in Manufacturing, R & D; and Commercial Operation Expansion